curl -X POST "http://localhost:8081/news" -H "accept: */*" -H "Content-Type: application/json" -d "{ \"author\": \"Anonymus\", \"creationDate\": \"2020-05-23T09:53:36.011Z\", \"id\": 0, \"keywords\": [ \"string\" ], \"paragraphs\": [ \"With millions of patients affected by COVID-19, the raging pandemic has put enormous pressure on critical medicine safety stocks. Healthcare workers are using every tool available to treat COVID-19 and related (or secondary) infections, resulting in a heavy pull on several medicines, including antibiotics. The pull on the system has been significant with increased demand for key medicines from patients and governments.\", \"We are proud that we have so far managed to ensure a dependable supply of medicines through swift action to increase production in the face of rapidly surging demand and multiple new obstacles throughout the supply chain\", \"Responding to these challenges, Sandoz, the Novartis generics and biosimilars division, has expanded its manufacturing capacity to maintain a stable supply of generic medicines for patients, while also delivering on a number of additional commitments to contribute to the global COVID-19 response.\", \"Sandoz, the single largest medicines provider in Europe and a leading player globally, took early action to ensure patients could access its portfolio of medicines, despite the crisis. Measures such as proactive increases in inventory of antibiotics and respiratory medicines are now helping the company navigate COVID-related supply chain issues and continue to meet patient needs. All Sandoz manufacturing sites and suppliers have continued full production and delivery throughout this crisis.\" ], \"title\": \"Sandoz responds to increased demand for antibiotics and other essential medicines for patients during COVID-19\"}"

curl -X POST "http://localhost:8081/news" -H "accept: */*" -H "Content-Type: application/json" -d "{ \"author\": \"Press Release\", \"creationDate\": \"2020-05-23T09:53:36.011Z\", \"id\": 0, \"keywords\": [ \"string\" ], \"paragraphs\": [ \"New York, NY, May 7, 2020 — As the global COVID-19 pandemic begins to reach fragile and conflict-affected countries, the International Rescue Committee (IRC) today announced a $1 million contribution by Novartis to its COVID-19 response efforts in Uganda, Kenya and Somalia. This funding will help the IRC mitigate the spread of the disease among some of East Africa's most vulnerable communities and ensure the IRC’s life-saving work can continue to reach those in need.\", \"David Miliband, President and CEO of the International Rescue Committee, said: “Given the nature of this emergency, the health and pharmaceutical sectors have a crucial role to play in helping front-line response organisations like the IRC rapidly detect, respond to, and prevent further spread of COVID-19.”\", \"“As innovators in health and medicine, Novartis has a unique understanding of the importance of basic protection measures in shoring up weak and vulnerable health systems against disease, and we are extremely grateful for their partnership and support.”\", \"Vas Narasimhan, CEO of Novartis, said: “We have a deep and longstanding commitment to reimagining medicine and medicine access in sub-Saharan Africa. COVID-19 is an unprecedented challenge for patients and health care systems around the world, and Novartis is supporting the IRC’s important work to help prevent the spread of the virus among vulnerable communities in Uganda, Kenya, and Somalia.\\\"\",\"The announcement comes as new IRC analysis estimates that without swift action in coming weeks, the world could see up to 1 billion infections and 3.2 million deaths due to COVID-19 over the course of the pandemic in 34 crisis-affected countries where the IRC works.\" ], \"title\": \"International Rescue Committee announces $1 million contribution from Novartis in support of COVID-19 response in East Africa\"}"

curl -X POST "http://localhost:8081/news" -H "accept: */*" -H "Content-Type: application/json" -d "{ \"author\": \"Novartis\", \"creationDate\": \"2020-04-28T10:00:27.046Z\", \"id\": 0, \"keywords\": [ \"covid19\", \"pneumonia\" ], \"paragraphs\": [ \"Novartis today announced plans to initiate a Phase III clinical trial to study canakinumab in patients with COVID-19 pneumonia. The CAN-COVID trial will examine the efficacy of utilizing canakinumab, an interleukin (IL)-1β blocker, to treat a type of severe immune overreaction called cytokine release syndrome (CRS) in people with COVID-19 pneumonia. CRS could lead to life-threatening complications in patients with COVID-19.\", \"The study builds on early evidence from lab tests of COVID-19 patients who showed elevated IL-1β levels, among other cytokines2,4.\", \"Novartis aims to rapidly enroll 450 patients at multiple medical centers across France, Germany, Italy, Spain, UK and the US and randomize them to receive either canakinumab or placebo on top of standard of care (SoC). The primary objective of the study is to demonstrate the benefit of canakinumab in combination with SoC in increasing the chance of survival without the need for invasive mechanical ventilation among patients with COVID-19 pneumonia. Top-line results are anticipated late summer 2020.\", \"This trial initiation is part of the overall Novartis approach to applying our best science to tackling the issues related to COVID-19 and further underscores Novartis commitment to quickly deploy R&D resources, medicines, clinical expertise and philanthropic aid to combat COVID-19.\" ], \"title\": \"Novartis announces plan to initiate clinical trial of canakinumab for patients with COVID-19 pneumonia\"}"